4.13
+0.03(+0.73%)
Currency In USD
| Previous Close | 4.1 |
| Open | 4.03 |
| Day High | 4.14 |
| Day Low | 3.63 |
| 52-Week High | 5.18 |
| 52-Week Low | 0.85 |
| Volume | 10.37M |
| Average Volume | 7.01M |
| Market Cap | 435.32M |
| PE | -14.75 |
| EPS | -0.28 |
| Moving Average 50 Days | 2.09 |
| Moving Average 200 Days | 1.78 |
| Change | 0.03 |
If you invested $1000 in SELLAS Life Sciences Group, Inc. (SLS) 10 years ago, it would be worth $0.15 as of January 07, 2026 at a share price of $4.13. Whereas If you bought $1000 worth of SELLAS Life Sciences Group, Inc. (SLS) shares 5 years ago, it would be worth $615.5 as of January 07, 2026 at a share price of $4.13.
For more details, use our stock calculator to calculate how much you would've made investing different amounts on specific dates.
SELLAS Life Sciences Provides Update on Pivotal Phase 3 REGAL Trial of Galinpepimut-S (GPS) in Acute Myeloid Leukemia (AML)
GlobeNewswire Inc.
Dec 29, 2025 1:35 PM GMT
Contract Research Organization for the REGAL trial has informed the Company that 72 events have occurred in the trial as of December 26, 2025; SELLAS remains blinded to trial outcomesTiming of the final analysis is event-driven, and SELLAS will annou
SELLAS Life Sciences Presents Positive Phase 2 Data of SLS009 in Combination with AZA/VEN in Relapsed/Refractory AML-MR at ASH 2025
GlobeNewswire Inc.
Dec 07, 2025 11:00 PM GMT
SLS009 in combination with AZA/VEN achieved a 46% overall response rate across all cohorts, a 58% overall response rate in patients with one prior line of therapy, and encouraging survival outcomes in heavily-pretreated AML-MR following prior VEN-bas
SELLAS Life Sciences Announces Presentation of Phase 2 Data of SLS009 in Combination with Azacitidine and Venetoclax in Relapsed/Refractory AML with MDS-Related Changes (AML-MR) at the 2025 American Society of Hematology (ASH) Annual Meeting
GlobeNewswire Inc.
Nov 03, 2025 2:00 PM GMT
NEW YORK, Nov. 03, 2025 (GLOBE NEWSWIRE) -- SELLAS Life Sciences Group, Inc. (NASDAQ: SLS) (“SELLAS’’ or the “Company”), a late-stage clinical biopharmaceutical company focused on the development of novel therapies for a broad range of cancer indic